Form 8-K - Current report:
SEC Accession No. 0000078003-25-000111
Filing Date
2025-04-29
Accepted
2025-04-29 08:02:49
Documents
16
Period of Report
2025-04-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pfe-20250429.htm   iXBRL 8-K 43815
2 EX-99 pfe-03302025xex99.htm EX-99 557361
7 pfizerlogoa.jpg GRAPHIC 38679
  Complete submission text file 0000078003-25-000111.txt   869698

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pfe-20250429.xsd EX-101.SCH 2618
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pfe-20250429_def.xml EX-101.DEF 15360
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pfe-20250429_lab.xml EX-101.LAB 27449
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pfe-20250429_pre.xml EX-101.PRE 16027
18 EXTRACTED XBRL INSTANCE DOCUMENT pfe-20250429_htm.xml XML 4452
Mailing Address 66 HUDSON BOULEVARD EAST NEW YORK NY 10001-2192
Business Address 66 HUDSON BOULEVARD EAST NEW YORK NY 10001-2192 2127332323
PFIZER INC (Filer) CIK: 0000078003 (see all company filings)

EIN.: 135315170 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-03619 | Film No.: 25882766
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)